Galangin alleviates vitiligo by targeting ANXA2 degradation in macrophages
Galangin bound to annexin A2 and promoted its degradation in macrophages, decreasing release of inflammatory factors and chemokines. These findings provide experimental evidence supporting the potential application of galangin in clinical treatments for vitiligo and highlight ANXA2 as a promising therapeutic target for managing this condition.
Authors
- Dengqiu Xu (ORCID: https://orcid.org/0000-0002-9502-0543)
- Ziqi Zhu (ORCID: https://orcid.org/0000-0001-8066-2052)
- Shixia Huo (ORCID: https://orcid.org/0000-0003-3519-1612)
- Zhijian Li (ORCID: https://orcid.org/0000-0002-4213-8054)
- Zehua Zhang
- Yong Zhu (ORCID: https://orcid.org/0000-0002-2829-0527)
- Wenjing Wei (ORCID: https://orcid.org/0000-0002-4990-3580)
- Zulipikaer Wusiman
- Xiangran Liu
- Yipeng Bai
- Abudureyimu Alimujiang
Institutions
- Shihezi University (CN)
- Anhui Medical University (CN)
- Xinjiang Uygur Autonomous Region Uygur Medicine Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1111/bph.70103
- Citations
- 1
- Primary Topic
- melanin and skin pigmentation
- Type
- article
- Field-Weighted Citation Impact
- 1.15
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province